Angiotensin-converting enzyme inhibitors from Salvia elegans Vahl

Ana Silvia Gutiérrez-Román, Manasés Gonzalez-Cortazar, Gabriela Trejo-Tapia, Maribel Herrera-Ruiz, Alejandro Zamilpa, Ernesto Sanchéz-Mendoza, Natividad Giovana De la Cruz- Sanchez, Enrique Jiménez-Ferrer

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


© 2020, © 2020 Informa UK Limited, trading as Taylor & Francis Group. Phytochemical research of the acetate and methanol extracts of the aerial parts (flowers, leaves and stems) of Salvia elegans allowed to obtain seventeen known compounds (1–17): three of them (4, 5, 14), had already been described for this species, while the others (1–3, 6–13, 15–17) are described for the first time for S. elegans. All isolated compounds were characterized using spectroscopic techniques and mass spectrometry and were evaluated in the Angiotensin I-converting enzyme (ACE) inhibition model, where the phenolic compounds (13, 14 and 15) had the same inhibitory effect as lisinopril at 0.02 mg/mL. The terpenes showed a moderate inhibitory capacity at a concentration of 0.2 mg/mL.
Original languageAmerican English
JournalNatural Product Research
StatePublished - 1 Jan 2020


Dive into the research topics of 'Angiotensin-converting enzyme inhibitors from Salvia elegans Vahl'. Together they form a unique fingerprint.

Cite this